AI assistant
Sending…
GlaxoSmithKline PLC — Interim / Quarterly Report 2021
Mar 30, 2021
5262_ffr_2021-03-30_9dc573ff-a5dc-4b22-86de-c985182a7638.zip
Interim / Quarterly Report
Open in viewerOpens in your device viewer
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2021
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
30 March 2021, London, U.K. GlaxoSmithKline plc (GSK) GSK publishes respiratory product sales reporting changes
Respiratory and HIV categories for reported sales to be updated To reflect the different stages of the product life-cycle of certain respiratory products and to ensure consistency of reporting for the sales of products with similar levels of strategic focus, the reporting of Relvar/Breo Ellipta along with the smaller Incruse Ellipta and Arnuity Ellipta product sales will with effect from the first quarter of 2021 be reported under the "Established Respiratory" section of our "Established Pharmaceuticals" category. Product sales of Trelegy Ellipta , Nucala and Anoro Ellipta will continue to be reported within the "Respiratory" category. In addition, the reporting of sales of Epzicom/Kivexa and Selzentry will going forward be incorporated into the "Other HIV" line within the "HIV category". The revised Pharmaceutical turnover tables below set out the revised format for reporting Pharmaceutical product sales that will be used from the first quarter 2021 results, in respect of the 2020 Pharmaceutical product sales. An Excel version of this data is available on www.gsk.com .
(GSK) - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
| Analyst/Investor enquiries: | +44 (0) 20 8047 2406 | (London) |
|---|---|---|
| Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
| Frannie DeFranco | +1 215 751 4855 | (Philadelphia) |
Brand names Brand names appearing in italics throughout this document are trademarks of GSK or associated companies or used under licence by the Group. This Announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The information for 2020 has been derived from the full Group accounts published in the Annual Report 2020. CER growth In order to illustrate underlying performance, it is the Group's practice to discuss its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the comparative period.
| Registered
in England & Wales: No. 3888792 |
| --- |
| Registered
Office: 980 Great West
Road Brentford,
Middlesex TW8 9GS |
Revised format for reporting Pharmaceuticals product sales
The revised format for the reporting of Pharmaceutical product sales applied to the 2020 Pharmaceutical sales is as follows:
Pharmaceuticals turnover - year ended 31 December 2020
| Total | US | Europe | International | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ------------------------------------- | ------------------------------------- | ------------------------------------- | ------------------------------------- | |||||||||
| Growth | Growth | Growth | Growth | |||||||||
| ----------------------- | ----------------------- | ----------------------- | ----------------------- | |||||||||
| £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Respiratory | 2,360 | 31 | 32 | 1,486 | 28 | 30 | 548 | 28 | 27 | 326 | 53 | 56 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Anoro Ellipta | 547 | 6 | 8 | 327 | 1 | 2 | 142 | 18 | 17 | 78 | 11 | 17 |
| Trelegy Ellipta | 819 | 58 | 59 | 561 | 47 | 48 | 168 | 65 | 65 | 90 | >100 | >100 |
| Nucala | 994 | 29 | 30 | 598 | 32 | 33 | 238 | 16 | 15 | 158 | 45 | 46 |
| HIV | 4,876 | - | 1 | 3,005 | - | 1 | 1,213 | 5 | 4 | 658 | (5) | (1) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Dolutegravir products | 4,702 | 1 | 2 | 2,941 | - | 1 | 1,163 | 7 | 6 | 598 | (2) | 3 |
| Tivicay | 1,527 | (8) | (7) | 871 | (11) | (10) | 368 | (7) | (8) | 288 | (1) | 5 |
| Triumeq | 2,306 | (10) | (9) | 1,454 | (10) | (9) | 568 | (9) | (10) | 284 | (9) | (6) |
| Juluca | 495 | 35 | 36 | 387 | 28 | 29 | 97 | 73 | 71 | 11 | 57 | 71 |
| Dovato | 374 | >100 | >100 | 229 | >100 | >100 | 130 | >100 | >100 | 15 | >100 | >100 |
| Rukobia | 11 | - | - | 11 | - | - | - | - | - | - | - | - |
| Cabenuva | - | - | - | - | - | - | - | - | - | - | - | - |
| Other | 163 | (26) | (25) | 53 | (20) | (18) | 50 | (29) | (27) | 60 | (29) | (28) |
| Immuno-Inflammation and Other Specialty | 727 | 19 | 20 | 612 | 14 | 16 | 56 | 22 | 20 | 59 | 84 | 91 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Benlysta | 719 | 17 | 19 | 612 | 14 | 16 | 56 | 22 | 20 | 51 | 59 | 66 |
| Oncology | 372 | 62 | 62 | 231 | 72 | 74 | 136 | 42 | 40 | 5 | - | - |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Zejula | 339 | 48 | 48 | 206 | 54 | 55 | 128 | 35 | 33 | 5 | - | - |
| Blenrep | 33 | - | - | 25 | - | - | 8 | - | - | - | - | - |
| New and Specialty Pharmaceuticals | 8,335 | 11 | 12 | 5,334 | 10 | 12 | 1,953 | 13 | 12 | 1,048 | 12 | 16 |
| Established Pharmaceuticals | 8,721 | (13) | (12) | 2,117 | (18) | (17) | 2,151 | (10) | (11) | 4,453 | (12) | (9) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Established Respiratory | 4,640 | (10) | (9) | 1,676 | (16) | (15) | 1,134 | (2) | (3) | 1,830 | (9) | (6) |
| Arnuity Ellipta | 45 | (6) | (6) | 37 | (10) | (7) | - | - | - | 8 | 14 | - |
| Avamys/Veramyst | 297 | (8) | (6) | - | - | - | 66 | (4) | (4) | 231 | (10) | (7) |
| Flixotide/Flovent | 419 | (33) | (32) | 183 | (50) | (50) | 80 | (9) | (10) | 156 | (10) | (5) |
| Incruse Ellipta | 220 | (16) | (15) | 117 | (27) | (27) | 74 | 1 | 1 | 29 | 4 | 7 |
| Relvar/Breo Ellipta | 1,124 | 16 | 17 | 474 | 24 | 25 | 322 | 14 | 13 | 328 | 6 | 9 |
| Seretide/Advair | 1,535 | (11) | (10) | 434 | (14) | (13) | 449 | (11) | (11) | 652 | (10) | (7) |
| Ventolin | 785 | (16) | (14) | 430 | (21) | (20) | 116 | (3) | (4) | 239 | (12) | (7) |
| Other Respiratory | 215 | (23) | (23) | 1 | >100 | >100 | 27 | (4) | - | 187 | (25) | (26) |
| Dermatology | 425 | (4) | (1) | 1 | (67) | (67) | 140 | (12) | (13) | 284 | - | 6 |
| Augmentin | 490 | (19) | (15) | - | - | - | 145 | (16) | (16) | 345 | (20) | (15) |
| Avodart | 466 | (19) | (17) | 5 | 25 | 25 | 158 | (24) | (25) | 303 | (16) | (13) |
| Imigran/Imitrex | 118 | (14) | (14) | 42 | (29) | (29) | 51 | (2) | (4) | 25 | (7) | (4) |
| Lamictal | 537 | (5) | (4) | 269 | (5) | (5) | 120 | 7 | 6 | 148 | (13) | (9) |
| Seroxat/Paxil | 146 | (9) | (6) | - | - | - | 37 | - | (3) | 109 | (11) | (7) |
| Valtrex | 103 | (4) | (2) | 15 | 7 | 7 | 32 | 3 | - | 56 | (10) | (5) |
| Other | 1,796 | (21) | (20) | 109 | (48) | (47) | 334 | (28) | (28) | 1,353 | (16) | (14) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Pharmaceuticals | 17,056 | (3) | (1) | 7,451 | 1 | 2 | 4,104 | (1) | (1) | 5,501 | (9) | (5) |
| -------- | -------- | -------- | -------- | ---------- | -------- | -------- | --------- | -------- | -------- | --------- | -------- |
Pharmaceuticals turnover - three months ended 31 December 2020
| Total | US | Europe | International | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ------------------------------------- | ------------------------------------- | ------------------------------------- | ------------------------------------- | |||||||||
| Growth | Growth | Growth | Growth | |||||||||
| ----------------------- | ----------------------- | ----------------------- | ----------------------- | |||||||||
| £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Respiratory | 681 | 28 | 29 | 435 | 25 | 27 | 150 | 23 | 19 | 96 | 60 | 63 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Anoro Ellipta | 151 | 7 | 8 | 90 | (1) | 1 | 39 | 18 | 15 | 22 | 29 | 29 |
| Trelegy Ellipta | 238 | 38 | 40 | 161 | 28 | 30 | 48 | 45 | 42 | 29 | >100 | >100 |
| Nucala | 292 | 34 | 34 | 184 | 39 | 42 | 63 | 13 | 7 | 45 | 50 | 53 |
| HIV | 1,268 | 1 | 2 | 805 | 3 | 5 | 327 | 10 | 6 | 136 | (24) | (21) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Dolutegravir products | 1,225 | 1 | 2 | 786 | 2 | 4 | 315 | 13 | 8 | 124 | (23) | (19) |
| Tivicay | 365 | (14) | (13) | 229 | (6) | (4) | 88 | (12) | (17) | 48 | (41) | (35) |
| Triumeq | 580 | (9) | (9) | 370 | (9) | (7) | 143 | (7) | (10) | 67 | (13) | (13) |
| Juluca | 139 | 25 | 25 | 108 | 21 | 22 | 28 | 47 | 37 | 3 | - | 33 |
| Dovato | 141 | >100 | >100 | 79 | >100 | >100 | 56 | >100 | >100 | 6 | >100 | >100 |
| Rukobia | 8 | - | - | 8 | - | - | - | - | - | - | - | - |
| Cabenuva | - | - | - | - | - | - | - | - | - | - | - | - |
| Other | 35 | (29) | (20) | 11 | (21) | - | 12 | (33) | (22) | 12 | (29) | (35) |
| Immuno-Inflammation and Other Specialty | 206 | 21 | 24 | 175 | 18 | 21 | 15 | 25 | 17 | 16 | 60 | 70 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Benlysta | 205 | 21 | 23 | 175 | 18 | 21 | 15 | 25 | 17 | 15 | 50 | 60 |
| Oncology | 115 | 74 | 74 | 75 | >100 | >100 | 37 | 28 | 21 | 3 | - | - |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Zejula | 89 | 35 | 35 | 54 | 46 | 51 | 32 | 10 | 3 | 3 | - | - |
| Blenrep | 25 | - | - | 20 | - | - | 5 | - | - | - | - | - |
| New and Specialty Pharmaceuticals | 2,270 | 12 | 13 | 1,490 | 13 | 16 | 529 | 15 | 11 | 251 | 1 | 5 |
| Established Pharmaceuticals | 2,096 | (17) | (16) | 484 | (25) | (23) | 528 | (10) | (13) | 1,084 | (17) | (15) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Established Respiratory | 1,092 | (18) | (17) | 373 | (27) | (26) | 278 | (3) | (7) | 441 | (16) | (14) |
| Arnuity Ellipta | 14 | (7) | (13) | 11 | (15) | (8) | - | - | - | 3 | 50 | (50) |
| Avamys/Veramyst | 70 | (3) | (1) | - | - | - | 15 | - | - | 55 | (7) | (5) |
| Flixotide/Flovent | 87 | (53) | (52) | 34 | (70) | (69) | 20 | (9) | (18) | 33 | (33) | (29) |
| Incruse Ellipta | 48 | (38) | (38) | 21 | (60) | (58) | 19 | 6 | - | 8 | 14 | 14 |
| Relvar/Breo Ellipta | 274 | 2 | 2 | 107 | - | 1 | 84 | 14 | 11 | 83 | (6) | (3) |
| Seretide/Advair | 351 | (15) | (15) | 73 | (30) | (28) | 105 | (12) | (16) | 173 | (9) | (7) |
| Ventolin | 211 | (7) | (5) | 125 | 1 | 3 | 29 | (6) | (13) | 57 | (20) | (15) |
| Other Respiratory | 37 | (45) | (48) | 2 | >100 | >100 | 6 | (33) | (11) | 29 | (50) | (53) |
| Dermatology | 109 | (3) | - | - | - | - | 36 | (10) | (12) | 73 | 1 | 7 |
| Augmentin | 115 | (27) | (24) | - | - | - | 37 | (21) | (26) | 78 | (30) | (23) |
| Avodart | 96 | (31) | (31) | 1 | >100 | >100 | 34 | (29) | (31) | 61 | (34) | (33) |
| Imigran/Imitrex | 27 | (23) | (26) | 6 | (60) | (60) | 14 | 8 | - | 7 | - | - |
| Lamictal | 140 | (3) | (3) | 73 | - | - | 30 | 7 | 4 | 37 | (16) | (11) |
| Seroxat/Paxil | 36 | (5) | (3) | - | - | - | 10 | 11 | - | 26 | (10) | (3) |
| Valtrex | 26 | (4) | (4) | 4 | - | - | 8 | - | (13) | 14 | (7) | - |
| Other | 455 | (18) | (17) | 27 | (27) | (16) | 81 | (25) | (25) | 347 | (15) | (14) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Pharmaceuticals | 4,366 | (4) | (3) | 1,974 | 1 | 3 | 1,057 | 1 | (3) | 1,335 | (14) | (12) |
| -------- | -------- | -------- | -------- | ---------- | -------- | -------- | --------- | -------- | -------- | --------- | -------- |
Pharmaceuticals turnover - nine months ended 30 September 2020
| Total | US | Europe | International | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ------------------------------------- | ------------------------------------- | ------------------------------------- | ------------------------------------- | |||||||||
| Growth | Growth | Growth | Growth | |||||||||
| ----------------------- | ----------------------- | ----------------------- | ----------------------- | |||||||||
| £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Respiratory | 1,679 | 32 | 33 | 1,051 | 30 | 31 | 398 | 30 | 31 | 230 | 50 | 53 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Anoro Ellipta | 396 | 6 | 8 | 237 | 2 | 2 | 103 | 18 | 18 | 56 | 6 | 13 |
| Trelegy Ellipta | 581 | 68 | 69 | 400 | 56 | 57 | 120 | 74 | 75 | 61 | >100 | >100 |
| Nucala | 702 | 28 | 28 | 414 | 29 | 30 | 175 | 17 | 17 | 113 | 43 | 43 |
| HIV | 3,608 | - | 1 | 2,200 | (1) | - | 886 | 3 | 3 | 522 | 1 | 6 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Dolutegravir products | 3,477 | 2 | 3 | 2,155 | (1) | - | 848 | 5 | 5 | 474 | 6 | 11 |
| Tivicay | 1,162 | (6) | (5) | 642 | (12) | (12) | 280 | (5) | (5) | 240 | 15 | 21 |
| Triumeq | 1,726 | (10) | (9) | 1,084 | (10) | (9) | 425 | (10) | (10) | 217 | (8) | (4) |
| Juluca | 356 | 40 | 41 | 279 | 30 | 31 | 69 | 86 | 89 | 8 | 100 | 100 |
| Dovato | 233 | >100 | >100 | 150 | >100 | >100 | 74 | >100 | >100 | 9 | >100 | >100 |
| Rukobia | 3 | - | - | 3 | - | - | - | - | - | - | - | - |
| Cabenuva | - | - | - | - | - | - | - | - | - | - | - | - |
| Other | 128 | (26) | (26) | 42 | (19) | (23) | 38 | (27) | (29) | 48 | (29) | (26) |
| Immuno-Inflammation and Other Specialty | 521 | 18 | 19 | 437 | 13 | 14 | 41 | 21 | 21 | 43 | 95 | 100 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Benlysta | 514 | 16 | 17 | 437 | 13 | 14 | 41 | 21 | 21 | 36 | 64 | 68 |
| Oncology | 257 | 57 | 57 | 156 | 61 | 62 | 99 | 48 | 48 | 2 | - | - |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Zejula | 250 | 53 | 53 | 152 | 57 | 57 | 96 | 45 | 45 | 2 | - | - |
| Blenrep | 8 | - | - | 5 | - | - | 3 | - | - | - | - | - |
| New and Specialty Pharmaceuticals | 6,065 | 11 | 12 | 3,844 | 9 | 10 | 1,424 | 12 | 13 | 797 | 16 | 20 |
| Established Pharmaceuticals | 6,625 | (12) | (10) | 1,633 | (15) | (15) | 1,623 | (10) | (10) | 3,369 | (11) | (7) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Established Respiratory | 3,548 | (8) | (6) | 1,303 | (12) | (12) | 856 | (2) | (2) | 1,389 | (7) | (4) |
| Arnuity Ellipta | 31 | (6) | (3) | 26 | (7) | (7) | - | - | - | 5 | - | 20 |
| Avamys/Veramyst | 227 | (10) | (7) | - | - | - | 51 | (6) | (6) | 176 | (11) | (8) |
| Flixotide/Flovent | 332 | (25) | (23) | 149 | (41) | (41) | 60 | (9) | (8) | 123 | (1) | 4 |
| Incruse Ellipta | 172 | (7) | (6) | 96 | (12) | (12) | 55 | - | 2 | 21 | - | 5 |
| Relvar/Breo Ellipta | 850 | 21 | 22 | 367 | 34 | 35 | 238 | 14 | 14 | 245 | 11 | 14 |
| Seretide/Advair | 1,184 | (10) | (8) | 361 | (9) | (9) | 344 | (10) | (10) | 479 | (10) | (7) |
| Ventolin | 574 | (19) | (17) | 305 | (28) | (27) | 87 | (2) | (1) | 182 | (9) | (3) |
| Other Respiratory | 178 | (16) | (16) | (1) | - | - | 21 | 11 | 5 | 158 | (18) | (18) |
| Dermatology | 316 | (5) | (2) | 1 | (67) | (67) | 104 | (13) | (13) | 211 | - | 6 |
| Augmentin | 375 | (16) | (12) | - | - | - | 108 | (14) | (13) | 267 | (16) | (12) |
| Avodart | 370 | (15) | (12) | 4 | - | - | 124 | (23) | (23) | 242 | (10) | (6) |
| Imigran/Imitrex | 91 | (12) | (11) | 36 | (18) | (18) | 37 | (5) | (5) | 18 | (10) | (5) |
| Lamictal | 397 | (6) | (4) | 196 | (7) | (6) | 90 | 7 | 7 | 111 | (12) | (8) |
| Seroxat/Paxil | 110 | (10) | (7) | - | - | - | 27 | (4) | (4) | 83 | (12) | (9) |
| Valtrex | 77 | (4) | (1) | 11 | 10 | 10 | 24 | 4 | 4 | 42 | (11) | (6) |
| Other | 1,341 | (23) | (21) | 82 | (52) | (53) | 253 | (29) | (29) | 1,006 | (16) | (13) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Pharmaceuticals | 12,690 | (2) | (1) | 5,477 | 1 | 1 | 3,047 | (1) | (1) | 4,166 | (7) | (3) |
| -------- | -------- | -------- | -------- | ---------- | -------- | -------- | --------- | -------- | -------- | --------- | -------- |
Pharmaceuticals turnover - three months ended 30 September 2020
| Total | US | Europe | International | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ------------------------------------- | ------------------------------------- | ------------------------------------- | ------------------------------------- | |||||||||
| Growth | Growth | Growth | Growth | |||||||||
| ----------------------- | ----------------------- | ----------------------- | ----------------------- | |||||||||
| £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Respiratory | 585 | 21 | 26 | 361 | 14 | 20 | 136 | 23 | 23 | 88 | 57 | 64 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Anoro Ellipta | 140 | (2) | 3 | 86 | (9) | (4) | 35 | 17 | 13 | 19 | - | 21 |
| Trelegy Ellipta | 194 | 40 | 45 | 126 | 20 | 29 | 42 | 50 | 54 | 26 | >100 | >100 |
| Nucala | 251 | 24 | 29 | 149 | 25 | 32 | 59 | 11 | 11 | 43 | 39 | 45 |
| HIV | 1,216 | (4) | - | 755 | (5) | - | 296 | 1 | 1 | 165 | (7) | 1 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Dolutegravir products | 1,176 | (3) | 1 | 739 | (5) | - | 284 | 3 | 4 | 153 | (2) | 5 |
| Tivicay | 377 | (15) | (10) | 220 | (18) | (13) | 87 | (15) | (14) | 70 | (1) | 7 |
| Triumeq | 577 | (11) | (8) | 368 | (11) | (6) | 135 | (12) | (13) | 74 | (11) | (5) |
| Juluca | 123 | 22 | 28 | 95 | 14 | 20 | 24 | 50 | 56 | 4 | >100 | 100 |
| Dovato | 99 | >100 | >100 | 56 | >100 | >100 | 38 | >100 | >100 | 5 | >100 | >100 |
| Rukobia | 3 | - | - | 3 | - | - | - | - | - | - | - | - |
| Cabenuva | - | - | - | - | - | - | - | - | - | - | - | - |
| Other | 37 | (34) | (32) | 13 | (24) | (24) | 12 | (33) | (39) | 12 | (43) | (33) |
| Immuno-Inflammation and Other Specialty | 193 | 13 | 18 | 158 | 5 | 11 | 15 | 25 | 25 | 20 | >100 | >100 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Benlysta | 186 | 8 | 13 | 158 | 5 | 11 | 15 | 25 | 25 | 13 | 30 | 40 |
| Oncology | 99 | 55 | 58 | 61 | 61 | 68 | 36 | 35 | 35 | 2 | >100 | >100 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Zejula | 92 | 44 | 47 | 57 | 50 | 55 | 33 | 27 | 27 | 2 | >100 | >100 |
| Blenrep | 8 | - | - | 5 | - | - | 3 | - | - | - | - | - |
| New and Specialty Pharmaceuticals | 2,093 | 5 | 10 | 1,335 | 2 | 8 | 483 | 9 | 9 | 275 | 14 | 21 |
| Established Pharmaceuticals | 2,099 | (17) | (13) | 583 | (13) | (9) | 491 | (18) | (18) | 1,025 | (20) | (12) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Established Respiratory | 1,118 | (11) | (6) | 471 | (8) | (3) | 253 | (8) | (8) | 394 | (17) | (9) |
| Arnuity Ellipta | 14 | 17 | 33 | 13 | 30 | 30 | - | - | - | 1 | (50) | 50 |
| Avamys/Veramyst | 56 | (15) | (8) | - | - | - | 13 | (13) | (13) | 43 | (16) | (6) |
| Flixotide/Flovent | 92 | (46) | (42) | 45 | (59) | (57) | 15 | (17) | (17) | 32 | (26) | (14) |
| Incruse Ellipta | 56 | (7) | (2) | 33 | (3) | 3 | 16 | (11) | (6) | 7 | (13) | (12) |
| Relvar/Breo Ellipta | 323 | 30 | 34 | 169 | 64 | 70 | 73 | 3 | 1 | 81 | 8 | 15 |
| Seretide/Advair | 368 | (12) | (8) | 112 | (4) | (1) | 104 | (14) | (14) | 152 | (16) | (8) |
| Ventolin | 177 | (23) | (18) | 100 | (26) | (22) | 25 | (7) | (4) | 52 | (24) | (15) |
| Other Respiratory | 32 | (40) | (28) | (1) | - | - | 7 | 75 | 50 | 26 | (46) | (38) |
| Dermatology | 110 | (7) | (1) | - | - | - | 36 | (10) | (13) | 74 | (5) | 5 |
| Augmentin | 106 | (30) | (24) | - | - | - | 30 | (21) | (21) | 76 | (33) | (25) |
| Avodart | 95 | (37) | (30) | 1 | (50) | (50) | 36 | (29) | (29) | 58 | (40) | (30) |
| Imigran/Imitrex | 30 | (17) | (14) | 11 | (27) | (27) | 12 | (8) | (8) | 7 | (13) | - |
| Lamictal | 125 | (15) | (10) | 61 | (18) | (12) | 30 | (3) | (3) | 34 | (19) | (10) |
| Seroxat/Paxil | 38 | (10) | (2) | - | - | - | 9 | (10) | (10) | 29 | (9) | - |
| Valtrex | 24 | (14) | (7) | 4 | - | - | 8 | (11) | (11) | 12 | (20) | (7) |
| Other | 453 | (26) | (22) | 35 | (44) | (46) | 77 | (41) | (40) | 341 | (18) | (13) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Pharmaceuticals | 4,192 | (7) | (3) | 1,918 | (3) | 2 | 974 | (6) | (6) | 1,300 | (14) | (7) |
| -------- | -------- | -------- | -------- | ---------- | -------- | -------- | --------- | -------- | -------- | --------- | -------- |
Pharmaceuticals turnover - six months ended 30 June 2020
| Total | US | Europe | International | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ------------------------------------- | ------------------------------------- | ------------------------------------- | ------------------------------------- | |||||||||
| Growth | Growth | Growth | Growth | |||||||||
| ----------------------- | ----------------------- | ----------------------- | ----------------------- | |||||||||
| £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Respiratory | 1,094 | 40 | 38 | 690 | 40 | 37 | 262 | 34 | 35 | 142 | 46 | 46 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Anoro Ellipta | 256 | 11 | 10 | 151 | 9 | 6 | 68 | 19 | 21 | 37 | 9 | 9 |
| Trelegy Ellipta | 387 | 87 | 85 | 274 | 81 | 77 | 78 | 90 | 90 | 35 | >100 | >100 |
| Nucala | 451 | 30 | 28 | 265 | 31 | 29 | 116 | 20 | 21 | 70 | 46 | 42 |
| HIV | 2,392 | 3 | 2 | 1,445 | 1 | (1) | 590 | 4 | 4 | 357 | 6 | 9 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Dolutegravir products | 2,301 | 4 | 3 | 1,416 | 2 | - | 564 | 6 | 6 | 321 | 10 | 14 |
| Tivicay | 785 | (1) | (2) | 422 | (9) | (11) | 193 | - | - | 170 | 24 | 28 |
| Triumeq | 1,149 | (9) | (10) | 716 | (9) | (11) | 290 | (9) | (9) | 143 | (6) | (3) |
| Juluca | 233 | 51 | 49 | 184 | 40 | 38 | 45 | >100 | >100 | 4 | 100 | 100 |
| Dovato | 134 | >100 | >100 | 94 | >100 | >100 | 36 | - | - | 4 | >100 | >100 |
| Rukobia | - | - | - | - | - | - | - | - | - | - | - | - |
| Cabenuva | - | - | - | - | - | - | - | - | - | - | - | - |
| Other | 91 | (22) | (23) | 29 | (17) | (23) | 26 | (24) | (24) | 36 | (23) | (23) |
| Immuno-Inflammation and Other Specialty | 328 | 21 | 19 | 279 | 18 | 16 | 26 | 18 | 18 | 23 | 77 | 77 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Benlysta | 328 | 21 | 19 | 279 | 18 | 16 | 26 | 18 | 18 | 23 | 92 | 92 |
| Oncology | 158 | 58 | 57 | 95 | 61 | 58 | 63 | 54 | 54 | - | - | - |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Zejula | 158 | 60 | 58 | 95 | 61 | 58 | 63 | 57 | 57 | - | - | - |
| Blenrep | - | - | - | - | - | - | - | - | - | - | - | - |
| New and Specialty Pharmaceuticals | 3,972 | 14 | 13 | 2,509 | 13 | 11 | 941 | 14 | 15 | 522 | 16 | 19 |
| Established Pharmaceuticals | 4,526 | (9) | (9) | 1,050 | (17) | (18) | 1,132 | (7) | (6) | 2,344 | (6) | (5) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Established Respiratory | 2,430 | (6) | (6) | 832 | (15) | (16) | 603 | - | 1 | 995 | (3) | (1) |
| Arnuity Ellipta | 17 | (19) | (24) | 13 | (28) | (28) | - | - | - | 4 | 33 | - |
| Avamys/Veramyst | 171 | (8) | (7) | - | - | - | 38 | (3) | (3) | 133 | (10) | (8) |
| Flixotide/Flovent | 240 | (12) | (12) | 104 | (27) | (29) | 45 | (6) | (4) | 91 | 12 | 14 |
| Incruse Ellipta | 116 | (7) | (8) | 63 | (16) | (19) | 39 | 5 | 5 | 14 | 8 | 15 |
| Relvar/Breo Ellipta | 527 | 16 | 16 | 198 | 16 | 14 | 165 | 20 | 20 | 164 | 13 | 14 |
| Seretide/Advair | 816 | (9) | (9) | 249 | (11) | (12) | 240 | (8) | (8) | 327 | (8) | (6) |
| Ventolin | 397 | (17) | (17) | 205 | (29) | (30) | 62 | - | - | 130 | (2) | 2 |
| Other Respiratory | 146 | (8) | (11) | - | - | - | 14 | (7) | (7) | 132 | (9) | (12) |
| Dermatology | 206 | (4) | (2) | 1 | (67) | (67) | 68 | (14) | (13) | 137 | 3 | 6 |
| Augmentin | 269 | (8) | (6) | - | - | - | 78 | (10) | (9) | 191 | (7) | (5) |
| Avodart | 275 | (3) | (3) | 3 | 50 | 50 | 88 | (19) | (19) | 184 | 6 | 7 |
| Imigran/Imitrex | 61 | (9) | (9) | 25 | (14) | (14) | 25 | (4) | (4) | 11 | (8) | (8) |
| Lamictal | 272 | (1) | (1) | 135 | (1) | (3) | 60 | 13 | 13 | 77 | (8) | (7) |
| Seroxat/Paxil | 72 | (10) | (10) | - | - | - | 18 | - | - | 54 | (13) | (13) |
| Valtrex | 53 | 2 | 2 | 7 | 17 | 17 | 16 | 14 | 14 | 30 | (6) | (6) |
| Other | 888 | (21) | (20) | 47 | (56) | (57) | 176 | (23) | (22) | 665 | (15) | (14) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Pharmaceuticals | 8,498 | - | - | 3,559 | 3 | 1 | 2,073 | 2 | 2 | 2,866 | (3) | (2) |
| -------- | -------- | -------- | -------- | ---------- | -------- | -------- | --------- | -------- | -------- | --------- | -------- |
Pharmaceuticals turnover - three months ended 30 June 2020
| Total | US | Europe | International | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ------------------------------------- | ------------------------------------- | ------------------------------------- | ------------------------------------- | |||||||||
| Growth | Growth | Growth | Growth | |||||||||
| ----------------------- | ----------------------- | ----------------------- | ----------------------- | |||||||||
| £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Respiratory | 574 | 30 | 27 | 378 | 34 | 30 | 122 | 17 | 18 | 74 | 32 | 27 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Anoro Ellipta | 139 | 9 | 6 | 88 | 9 | 5 | 32 | 7 | 10 | 19 | 12 | 6 |
| Trelegy Ellipta | 194 | 62 | 58 | 140 | 65 | 60 | 36 | 64 | 59 | 18 | 38 | 46 |
| Nucala | 241 | 24 | 21 | 150 | 28 | 26 | 54 | 4 | 6 | 37 | 42 | 31 |
| HIV | 1,185 | (2) | (3) | 740 | 1 | (2) | 270 | (7) | (7) | 175 | (5) | (2) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Dolutegravir products | 1,140 | (1) | (2) | 725 | 1 | (2) | 259 | (4) | (5) | 156 | - | 4 |
| Tivicay | 373 | (9) | (10) | 208 | (14) | (16) | 87 | (12) | (14) | 78 | 10 | 15 |
| Triumeq | 586 | (9) | (11) | 378 | (6) | (9) | 134 | (16) | (16) | 74 | (12) | (10) |
| Juluca | 113 | 35 | 33 | 90 | 29 | 27 | 21 | 62 | 62 | 2 | 100 | >100 |
| Dovato | 68 | >100 | >100 | 49 | >100 | >100 | 17 | - | - | 2 | >100 | >100 |
| Rukobia | - | - | - | - | - | - | - | - | - | - | - | - |
| Cabenuva | - | - | - | - | - | - | - | - | - | - | - | - |
| Other | 45 | (27) | (32) | 15 | (6) | (19) | 11 | (39) | (39) | 19 | (32) | (36) |
| Immuno-Inflammation and Other Specialty | 177 | 17 | 15 | 153 | 16 | 14 | 12 | 9 | - | 12 | 50 | 50 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Benlysta | 177 | 18 | 15 | 153 | 16 | 14 | 12 | 9 | - | 12 | 71 | 71 |
| Oncology | 77 | 35 | 33 | 47 | 42 | 39 | 30 | 25 | 21 | - | - | - |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Zejula | 77 | 35 | 32 | 47 | 42 | 39 | 30 | 25 | 21 | - | - | - |
| Blenrep | - | - | - | - | - | - | - | - | - | - | - | - |
| New and Specialty Pharmaceuticals | 2,013 | 8 | 6 | 1,318 | 11 | 9 | 434 | 2 | 1 | 261 | 5 | 6 |
| Established Pharmaceuticals | 2,089 | (15) | (15) | 483 | (19) | (21) | 497 | (18) | (19) | 1,109 | (11) | (9) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Established Respiratory | 1,114 | (9) | (9) | 377 | (15) | (17) | 276 | (7) | (8) | 461 | (4) | (2) |
| Arnuity Ellipta | 8 | (43) | (50) | 6 | (50) | (50) | - | - | - | 2 | - | (50) |
| Avamys/Veramyst | 62 | (13) | (10) | - | - | - | 19 | (5) | (10) | 43 | (16) | (10) |
| Flixotide/Flovent | 117 | (7) | (7) | 54 | (17) | (18) | 17 | (23) | (18) | 46 | 18 | 18 |
| Incruse Ellipta | 59 | 4 | 2 | 33 | 6 | - | 19 | - | - | 7 | - | 14 |
| Relvar/Breo Ellipta | 242 | 2 | 2 | 83 | (11) | (12) | 78 | 11 | 9 | 81 | 8 | 12 |
| Seretide/Advair | 421 | 2 | 2 | 143 | 36 | 34 | 113 | (12) | (13) | 165 | (7) | (6) |
| Ventolin | 144 | (39) | (39) | 58 | (59) | (60) | 24 | (17) | (21) | 62 | (6) | (2) |
| Other Respiratory | 61 | (10) | (16) | - | - | - | 6 | (25) | (12) | 55 | (10) | (16) |
| Dermatology | 95 | (11) | (9) | 1 | - | - | 30 | (27) | (24) | 64 | (2) | - |
| Augmentin | 100 | (25) | (23) | - | - | - | 21 | (45) | (45) | 79 | (17) | (17) |
| Avodart | 134 | (5) | (6) | 2 | 100 | 100 | 39 | (26) | (28) | 93 | 7 | 7 |
| Imigran/Imitrex | 27 | (25) | (28) | 10 | (41) | (41) | 12 | (8) | (15) | 5 | (17) | (17) |
| Lamictal | 135 | (5) | (6) | 66 | (8) | (10) | 28 | - | (4) | 41 | (2) | (2) |
| Seroxat/Paxil | 36 | (10) | (10) | - | - | - | 8 | (11) | (11) | 28 | (10) | (10) |
| Valtrex | 25 | - | - | 3 | >100 | >100 | 7 | - | - | 15 | (12) | (12) |
| Other | 423 | (30) | (29) | 24 | (61) | (62) | 76 | (37) | (36) | 323 | (23) | (22) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Pharmaceuticals | 4,102 | (5) | (5) | 1,801 | 1 | (1) | 931 | (10) | (11) | 1,370 | (8) | (7) |
| -------- | -------- | -------- | -------- | ---------- | -------- | -------- | --------- | -------- | -------- | --------- | -------- |
Pharmaceuticals turnover - three months ended 31 March 2020
| Total | US | Europe | International | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ------------------------------------- | ------------------------------------- | ------------------------------------- | ------------------------------------- | |||||||||
| Growth | Growth | Growth | Growth | |||||||||
| ----------------------- | ----------------------- | ----------------------- | ----------------------- | |||||||||
| £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | £m | £% | CER% | |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Respiratory | 520 | 52 | 52 | 312 | 49 | 47 | 140 | 54 | 55 | 68 | 66 | 73 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Anoro Ellipta | 117 | 15 | 16 | 63 | 9 | 9 | 36 | 33 | 33 | 18 | 6 | 12 |
| Trelegy Ellipta | 193 | >100 | >100 | 134 | >100 | >100 | 42 | >100 | >100 | 17 | >100 | >100 |
| Nucala | 210 | 38 | 38 | 115 | 35 | 33 | 62 | 38 | 38 | 33 | 50 | 55 |
| HIV | 1,207 | 8 | 8 | 705 | 2 | 1 | 320 | 15 | 17 | 182 | 18 | 21 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Dolutegravir products | 1,161 | 9 | 9 | 691 | 3 | 2 | 305 | 16 | 18 | 165 | 22 | 25 |
| Tivicay | 412 | 8 | 8 | 214 | (4) | (5) | 106 | 13 | 15 | 92 | 39 | 42 |
| Triumeq | 563 | (8) | (8) | 338 | (12) | (13) | 156 | (3) | (1) | 69 | 1 | 4 |
| Juluca | 120 | 71 | 69 | 94 | 54 | 51 | 24 | >100 | >100 | 2 | 100 | 100 |
| Dovato | 66 | - | - | 45 | - | - | 19 | - | - | 2 | - | - |
| Rukobia | - | - | - | - | - | - | - | - | - | - | - | - |
| Cabenuva | - | - | - | - | - | - | - | - | - | - | - | - |
| Other | 46 | (15) | (13) | 14 | (26) | (26) | 15 | (6) | (6) | 17 | (11) | (5) |
| Immuno-Inflammation and Other Specialty | 151 | 25 | 24 | 126 | 20 | 18 | 14 | 27 | 36 | 11 | >100 | >100 |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Benlysta | 151 | 25 | 24 | 126 | 20 | 18 | 14 | 27 | 36 | 11 | >100 | >100 |
| Oncology | 81 | 88 | 88 | 48 | 85 | 81 | 33 | 94 | 100 | - | - | - |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Zejula | 81 | 93 | 93 | 48 | 85 | 81 | 33 | >100 | >100 | - | - | - |
| Blenrep | - | - | - | - | - | - | - | - | - | - | - | - |
| New and Specialty Pharmaceuticals | 1,959 | 20 | 20 | 1,191 | 16 | 14 | 507 | 28 | 29 | 261 | 31 | 35 |
| Established Pharmaceuticals | 2,437 | (4) | (3) | 567 | (14) | (15) | 635 | 5 | 6 | 1,235 | (2) | (1) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Established Respiratory | 1,316 | (4) | (4) | 455 | (14) | (15) | 327 | 8 | 10 | 534 | (1) | (1) |
| Arnuity Ellipta | 9 | 29 | 29 | 7 | 17 | 17 | - | - | - | 2 | 100 | 100 |
| Avamys/Veramyst | 109 | (5) | (5) | - | - | - | 19 | - | 5 | 90 | (6) | (7) |
| Flixotide/Flovent | 123 | (16) | (16) | 50 | (36) | (37) | 28 | 8 | 8 | 45 | 7 | 10 |
| Incruse Ellipta | 57 | (16) | (16) | 30 | (32) | (32) | 20 | 11 | 11 | 7 | 17 | 17 |
| Relvar/Breo Ellipta | 285 | 33 | 32 | 115 | 47 | 45 | 87 | 30 | 33 | 83 | 19 | 16 |
| Seretide/Advair | 395 | (19) | (18) | 106 | (40) | (40) | 127 | (5) | (3) | 162 | (8) | (7) |
| Ventolin | 253 | 3 | 4 | 147 | 1 | (1) | 38 | 15 | 18 | 68 | 3 | 6 |
| Other Respiratory | 85 | (7) | (8) | - | - | - | 8 | 14 | - | 77 | (8) | (8) |
| Dermatology | 111 | 3 | 6 | - | - | - | 38 | - | - | 73 | 7 | 12 |
| Augmentin | 169 | 6 | 8 | - | - | - | 57 | 16 | 18 | 112 | 1 | 3 |
| Avodart | 141 | (1) | - | 1 | - | - | 49 | (13) | (11) | 91 | 6 | 7 |
| Imigran/Imitrex | 34 | 10 | 13 | 15 | 25 | 25 | 13 | - | 8 | 6 | - | - |
| Lamictal | 137 | 4 | 5 | 69 | 6 | 5 | 32 | 28 | 32 | 36 | (14) | (12) |
| Seroxat/Paxil | 36 | (10) | (10) | - | - | - | 10 | 11 | 11 | 26 | (16) | (16) |
| Valtrex | 28 | 4 | 4 | 4 | (20) | (20) | 9 | 29 | 29 | 15 | - | - |
| Other | 465 | (10) | (9) | 23 | (51) | (51) | 100 | (6) | (7) | 342 | (6) | (4) |
| -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | -------- | |
| Pharmaceuticals | 4,396 | 6 | 6 | 1,758 | 4 | 3 | 1,142 | 14 | 15 | 1,496 | 2 | 4 |
| -------- | -------- | -------- | -------- | ---------- | -------- | -------- | --------- | -------- | -------- | --------- | -------- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| (Registrant) |
| Date: March |
| 30, 2021 |
| By:/s/ VICTORIA |
| WHYTE -------------------------- |
| Victoria Whyte |
| Authorised |
| Signatory for and on |
| behalf |
| of GlaxoSmithKline plc |
page break
More from GlaxoSmithKline PLC
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 1
Transaction in Own Shares
2026
Jun 1
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 1
Transaction in Own Shares
2026
Jun 1
Regulatory Filings
2026
May 28
Regulatory Filings
2026
May 28
Director's Dealing
2026
May 27
Director's Dealing
2026
May 27
Regulatory Filings
2026
May 26
Share Issue/Capital Change
2026
May 26